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SARM1 an executor of axonal degeneration, displays NADase activity that depletes the key 29 
cellular metabolite, NAD+, in response to nerve injury. The basis of SARM1 inhibition, and its 30 
activation under stress conditions are still unknown. Here, we present cryo-EM maps of SARM1 31 
at 2.9 and 2.7 Å resolution. These indicate that SARM1 homo-octamer avoids premature 32 
activation by assuming a packed conformation, with ordered inner and peripheral rings, that 33 
prevents dimerization and activation of the catalytic domains. This inactive conformation is 34 
stabilized by binding of SARM1’s own substrate NAD+ in an allosteric location, away from the 35 
catalytic sites. This model was validated by mutagenesis of the allosteric site, which led to 36 
constitutively active SARM1. We propose that the reduction of cellular NAD+ concentration 37 
contributes to the disassembly of SARM1's peripheral ring, which allows formation of active 38 
NADase domain dimers, thereby further depleting NAD+ to cause an energetic catastrophe and 39 
cell death. 40 
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52 
Introduction 53 
SARM1 (sterile α and HEAT/armadillo motif–containing protein (Mink et al., 2001)) was first 54 
discovered as a negative regulator of TRIF (TIR domain–containing adaptor inducing interferon-55 
β) in TLR (Toll-like receptor) signaling (Carty et al., 2006). SARM1 was later shown to promote 56 
neuronal death by oxygen and glucose deprivation (Kim et al., 2007) and viral infections (Hou et 57 
al., 2013; Mukherjee et al., 2013; Sundaramoorthy et al., 2020; Uccellini et al., 2020), while also 58 
having a protective role against bacterial and fungal infections in C. elegans (Couillault et al., 59 
2004; Liberati et al., 2004). Subsequently, studies have demonstrated that SARM1 is also a key 60 
part of a highly conserved axonal death pathway that is activated by nerve injury (Gerdts et al., 61 
2013; Osterloh et al., 2012). Notably, SARM1 deficiency confers protection against axonal 62 
degeneration in several models of neurodegenerative conditions (Kim et al., 2007; Ko et al., 63 
2020; Ozaki et al., 2020; Uccellini et al., 2020), making SARM1 a compelling drug target to 64 
protect axons in a variety of axonopathies (Krauss et al., 2020; Loring et al., 2020). 65 
The domain composition of SARM1 includes an N-terminal peptide, an ARM-repeats region, two 66 
SAM and one TIR domain (Figure 1A, Figure 1 - Figure supplement 1), which mediate 67 
mitochondria targeting (Panneerselvam et al., 2012), auto-inhibition (Chuang and Bargmann, 68 
2005; Summers et al., 2016), oligomerization (Gerdts et al., 2013), and NADase activity (Gerdts 69 
et al., 2015), respectively.  70 
Amino acid substitutions (E642A or E596K) at the TIR domain’s active site abolish the NADase 71 
activity in vitro and inactivates SARM1 pro-degenerative activity (Essuman et al., 2017; Geisler et 72 
al., 2019; Horsefield et al., 2019), thereby linking SARM1’s role in axonal degeneration with its 73 
NADase activity. The enzymatic activity requires a high local concentration of the TIR domains, 74 
as demonstrated by forced dimerization of TIR, which resulted in NAD+ hydrolysis and neuronal 75 
cell death (Gerdts et al., 2015; Gerdts et al., 2016). Also, the deletion of the ARM domain in 76 
SARM1, which interacts directly with TIR (Summers et al., 2016), renders the ‘delARM’ construct 77 
constitutively active and leads to rapid cell death (Gerdts et al., 2013; Sporny et al., 2019). How 78 
SAM domains cause TIR crowding became clearer in our recent report (Sporny et al., 2019), 79 
where we showed that both hSARM1 (human SARM1) and the isolated tandem SAM1-2 domains 80 
form octamers in solution. In this study, we used negative stain electron microscopy analysis of 81 
hSARM1 and determined the crystal structure (as did others (Horsefield et al., 2019)) of the 82 
SAM1-2 domains - both of which revealed an octameric ring arrangement. 83 
These findings imply that hSARM1 is kept auto-inhibited by the ARM domain in homeostasis, and 84 
gains NADase activity upon stress conditions through: the infliction of injury (axotomy (Osterloh et 85 
al., 2012)), oxidation (mitochondria depolarization (Murata et al., 2013); oxidizing agents 86 
(Summers et al., 2014)), metabolic conditions (depletion of NAD+ (Gilley et al., 2015)), or toxins 87 
(chemotherapy drugs (Geisler et al., 2016)). Whether and how all or some of these insults 88 
converge to induce SARM1 activation is still not completely understood. In this regard, little is 89 
known about the direct molecular triggers of SARM1 in cells, besides the potential involvement of 90 
nicotinamide mononucleotide (NMN) (Bratkowski et al., 2020; Liu et al., 2018a; Zhao et al., 2019) 91 
and Ser-548 phosphorylation by JNK (Murata et al., 2018) in promoting the NADase activity of 92 
SARM1. Here we present structural data and complementary biochemical assays, to show that 93 
SARM1 is kept inactive through a ‘substrate inhibition’ mechanism, where the high concentration 94 
of NAD+ stabilizes the tightly packed, inhibited conformation of the protein. In this way, SARM1 95 
activation is triggered by a decrease in the concentration of a cellular metabolite - NAD+, rather 96 
than depend on the introduction of an activating factor.  97 
 98 
Results 99 
Cryo-EM visualization of purified hSARM1 100 
For cryo-EM imaging, we generated a near-intact hSARM1 construct, that lacks the N-terminal 101 
mitochondrial localization signal (26ERL…GPT724) and has a point mutant in the NADase catalytic 102 
site (E642Q). The resulting construct was expressed in mammalian cell culture and isolated to 103 
homogeneity using consecutive metal chelate and size exclusion chromatography steps. For 104 
cellular and in vitro activity assays we expressed and isolated hSARM1w.t. (26ERL…GPT724) 105 
without the E642 mutation (Figure 1B, Figure 1 - Figure supplement 1), although with lower 106 
yields. We first collected cryo-EM images of the purified hSARM1E642Q. 2D classification (Figure 107 
1C) and 3D reconstruction (Figure 1D, Table 1) revealed an octamer ring assembly with clearly 108 
visible inner ring, which is attributed to the tandem SAM domains. Only a minor fraction of the 109 
particles (~20%) shows the presence of a (partial) peripheral ring composed by the ARM and TIR 110 
domains. Cryo-EM analysis of the isolated SAM1-2 domains (Figure 1D), and docking of the 111 
crystal structure of the SAM1-2 octamer (PDB code 6QWV) into the 3D maps demonstrates that 112 
indeed, the ARM and TIR domains are largely missing from this reconstruction, implying a 113 
disordered peripheral ring in ~80% of the particles. Exploring different buffers, pH and salt 114 
conditions, addition of various detergents, as well as variations in cryo-EM grid preparation (e.g. 115 
ice thickness) did not affect the visibility of the octamer peripheral ring considerably.    116 
These results are inconsistent with our previous analysis, where we used low resolution negative 117 
stain EM visualization and 2D classification of hSARM1E642Q that showed fully assembled inner 118 
and outer ring structures (Figure 1C) (Sporny et al., 2019). We thought, that a glycerol-gradient 119 
fixation step (GraFix (Kastner et al., 2008)) that involves ultra-centrifugation of the protein sample 120 
through a glycerol + glutaraldehyde cross-linker gradients, which was applied before the negative 121 
stain - but not before the cryo-EM sample preparations - might be the cause for the difference 122 
between the two imaging conditions. We therefore pursued cryo-EM data collection of GraFix-ed 123 
hSARM1E642Q after dilution of the glycerol from 18% (which severely diminishes protein contrast in 124 
cryo-EM) to 2.5%.  125 
 126 
2.88 Å resolution structure of a fully assembled compact hSARM1 GraFix-ed octamer 127 
We carried out 2D classification (Figure 2A), and 3D reconstruction and refinement (Figure 2B-D, 128 
Table 1) of the GraFix-ed hSARM1E642Q to an overall resolution of 2.88 Å (applying 8-fold 129 
symmetry). The hSARM1E642Q octamer is 203 Å in diameter and 80 Å thick (Figure 2 - Figure 130 
supplement 1A). The SAM1-2 domains’ inner ring is the best resolved part of the map, to which the 131 
high-resolution crystal structure (PDB code 6QWV) was fitted with minute adjustments. The TIR 132 
domains are the least defined part of the density map. Some parts of the TIR domain reach a 133 
local resolution of 6.5 Å (Figure 2 - Figure supplement 2A), and therefore not revealing side chain 134 
positions. However, the availability of high-resolution crystal structures of isolated hSARM1 TIR 135 
(PDB codes 6O0R, 6O0U (Horsefield et al., 2019)) allowed their docking into the well resolved 136 
secondary structure elements in the map with very high confidence. The ARM domains show 137 
intermediate map quality, with well resolved secondary structures and bulky sidechains. This 138 
allowed the building of a de-novo atomic model for the entire ARM, as no high-resolution 139 
structure or homology models of SARM1’s ARM are available. The entire atomic model is 140 
comprised of residues 56-700 (Figure 1 - Figure supplement 1), with an internal break at the 141 
linker that connects SAM2 to the TIR domain. The structural analyses of the SAM domains and 142 
the SAM octamer ring assembly, as well as the atomic details of the TIR domain, are described in 143 
our previous study, and by others (Horsefield et al., 2019; Sporny et al., 2019). The cryo-EM 144 
structure of the ARM domain reveals a closed crescent-shaped region, composed of seven three-145 
helix ARM repeats spanning residues 60-400 (Figure 2 - Figure supplement 1B). The ARM 146 
topology is split into two interacting parts, designated ARM1 (res. 60-303 with five ARM repeats) 147 
and ARM2 (res. 322-400 with two ARM repeats) (Figure 1 - Figure supplement 1). The main 148 
ARM1 - ARM2 interaction interface is hydrophobic and involves helices 14 and 16 of ARM1 and 149 
helices 1, 2 and 3 of ARM2. ARM1 and ARM2 are also interacting at the crescent ‘horns’ through 150 
the ARM1 2-3 loop with the loop that connects ARM1 with ARM2 (res. 305-320). In the 151 
hSARM1 compact octamer, each ARM is directly connected via a linker (res. 400-404) to a SAM1 152 
domain. Also, each ARM is engaged in several non-covalent interactions with the same-chain 153 
SAM and with the clockwise neighboring SAM, when assuming a top view of the structure (Figure 154 
2B-D). Although neighboring ARM domains are closely packed, direct interactions between them 155 
seem to be limited, engaging a short segment of ARM1 9 with the 4-5 loop of ARM2 of the 156 
neighboring chain. Additional ARM-ARM interactions are indirect, mediated by the TIR domains. 157 
Each TIR binds the ARM ring via two sites, designated the ‘primary’ and ‘secondary’ TIR docking 158 
sites (Figure 3A). The ‘primary’ is larger and engages the TIR helix A and the EE loop with the 159 
ARM1 10, 10-11 loop and 13. The ‘secondary’ TIR docking site is smaller and involves the 160 
TIR BB loop and helix 7 of the counter-clockwise ARM1 domain (Figure 1 - Figure supplement 161 
1). 162 
Very recently, (Bratkowski et al., 2020) have reported a 3.3 Å cryo-EM structure of hSARM150-724. 163 
Except for a residue registry shift throughout the ARM1 𝛂1-4 and a minor one at the ARM1-ARM2 164 
loop, their structure is largely similar to our 2.88 Å GraFix-ed structure. While we have used the 165 
GraFix pre-treatment to coerce the compact two-ring conformation, it seems that Bratkowski et. 166 
al. employed a different strategy by selectively using a small subset (5.6%) of the initial picked 167 
particles to reconstruct their map. We assume that this was done to cope with the particle 168 
heterogeneity of purified SARM1. An obstacle we have encountered as well, where we observed 169 
that ~80% of the particles have a disordered outer ring. 170 
 171 
The compact conformation of hSARM1 is inhibited for NADase activity 172 
The GraFix-ed cryo-EM structure revealed a domain organization where the catalytic TIR 173 
subunits are separated from each other by docking onto the ARM peripheral ring. This assembly 174 
is dependent on the coupling of each TIR with two neighboring ARM domains (Figure 3A). Since 175 
the NADase activity requires close proximity of several of TIR domains (Bratkowski et al., 2020; 176 
Gerdts et al., 2015; Gerdts et al., 2016), and possibly homo-dimerization (Horsefield et al., 2019), 177 
we considered that the cryo-EM structure represents an inhibited conformation of SARM1, in 178 
which the TIR domains cannot form compact dimers and catabolize NAD+. To test this 179 
hypothesis, we aimed to weaken TIR docking to allow their nearing and subsequent NAD+ 180 
catalysis. To this end we designed amino acid substitutions at the ARM’s primary TIR docking 181 
site without compromising the protein’s structural integrity – particularly that of the TIR domain 182 
(Figure 3A). Two pairs of mutations - RR216-7EE of ARM1 helix 10, and FP255-6RR of ARM1 183 
helix 13 (Figure 3C, Figure 1 - Figure supplement 1) were introduced, as well as the double 184 
mutant RR216-7EE/FP255-6RR. These constructs were transiently expressed in HEK-293T cells. 185 
The effect of these constructs on NAD+ levels and cell viability were monitored using a previously 186 
established resazurin fluorescence assay (Essuman et al., 2018; Gerdts et al., 2013; Sporny et 187 
al., 2019). The results (Figure 3C) show a rapid decrease in cellular NAD+ levels and 50% cell 188 
death within 24 hours after transfection of the FP255-6RR and double mutant. This toxicity level 189 
is similar to that of a hSARM1 construct missing the entire ARM domain ‘delARM’ (res. 409–724) 190 
(Figure 3C), proven to be toxic in neurons and HEK293 cells (Gerdts et al., 2013; Sporny et al., 191 
2019). This toxic effect was attributed to the removal of auto-inhibitory constraints imposed by the 192 
ARM domain. The RR216-7EE mutation has a weaker effect, probably due to the position of 193 
these amino acid residues at the margin of the TIR-ARM interface.  194 
In conclusion, we found that hSARM1 inhibition requires ARM-TIR interaction through the 195 
‘primary TIR docking site’. This conclusion is supported by other recently published reports 196 
(Bratkowski et al., 2020; Jiang et al., 2020). We further calculated the surface conservation 197 
scores of SARM1 orthologs. The scores were color coded and plotted on the molecular surface of 198 
hSARM1 using the Consurf server (Figure 3B)(Ashkenazy et al., 2016). The surface-exposed 199 
residues reveal a high level of conservation on both the ARM and TIR domain binding interface. 200 
This indicates the biological importance of the interface and a possible conservation of its 201 
function in auto-inhibition among species. It was previously suggested, that auto-inhibition of 202 
SARM1 is maintained by keeping SARM1 as a monomer, and that upon activation SARM1 203 
assembles into a multimer (Figley and DiAntonio, 2020), very much like other apoptotic 204 
complexes. Our results show otherwise, and explain how hSARM1 avoids premature activation 205 
even as a pre-formed octamer, while kept poised for rapid activation and response. 206 
 207 
Isolated hSARM1 is NADase active in vitro and inhibited by glycerol 208 
As it became clear that the compact two-ring structure is inhibited for NADase activity, we 209 
considered whether the purified hSARM1, that was not subjected to GraFix, and predominantly 210 
presents just the inner SAM ring in cryo-EM 2D averaging and 3D reconstruction (Figure 1C,D), 211 
is active in vitro. Using a resazurin fluorescence assay modified for an in vitro application, we 212 
measured the rate of NAD+ consumption by hSARM1w.t. in a series of NAD+ concentrations and 213 
determined a Km of 28±4 µM, with Vmax of 9±0.3 µM/min and Kcat of 46.49 1/min (Figure 3D). 214 
These kinetic parameters are remarkably similar to a published Km of 24 µM (Essuman et al., 215 
2017) – especially when considering that the quoted study used an isolated TIR domain fused to 216 
artificial dimerizing and aggregating agents, while we used the near-intact protein.  217 
It was previously discovered that nicotinamide mononucleotide (NMN) levels rises after axonal 218 
injury, and that exogenous increase of NMN induces degeneration (Di Stefano et al., 2015). 219 
Moreover, a membrane-permeable NMN analogue activates SARM1 in cultured cells, leading to 220 
their death (Liu et al., 2018a; Zhao et al., 2019). We therefore measured the effect of NMN 221 
supplement on the NADase activity of purified hSARM1 and found a moderate 30% increase in 222 
activity with 1 mM NMN, but none at a lower concentration of 200 µM (Figure 3E). This 223 
demonstrates that the purified hSARM1 is mostly NADase active, even without NMN supplement, 224 
supporting the idea of a predominantly open conformation as seen in cryo-EM (Figure 1C,D).  225 
Next, we examined what confines the GraFix-ed hSARM1 into the compact inhibited 226 
conformation (Figure 2), and measured the in vitro NADase activity in the presence of glycerol 227 
(Figure 3F). We found that glycerol reduces hSARM1 NADase activity in a concentration-228 
dependent manner, reaching 72% inhibition at 15% glycerol. In the GraFix preparation, we 229 
extracted hSARM1 from the gradient after it migrated to approximately 18% glycerol 230 
concentration. This is the position we used to image SARM1 in its inhibited compact 231 
conformation. It seems likely, that this conformation is maintained after glycerol is removed, due 232 
to glutaraldehyde crosslinking which preserves the compact structure.  233 
 234 
NAD+ substrate inhibition of hSARM1  235 
Our results show that hSARM1 NADase activity is suppressed in cell culture, but much less so in 236 
vitro after being isolated. This prompted us to hypothesize that in the course of purification from 237 
the cytosolic fraction, hSARM1 loses a low-affinity cellular factor, responsible for inhibiting it in the 238 
cellular environment. SARM1 was previously shown to be activated in cell culture in response to 239 
metabolic, toxic and oxidative stressors. We reasoned that the hypothesized inhibitory factor is a 240 
small molecule that is depleted under cellular stress conditions and thus, the inhibition of 241 
hSARM1 is released. To follow through on this hypothesis, we tested the impact of several small 242 
molecules, which are associated with the cell’s energetic state, with two in vitro parameters: 243 
hSARM1 NADase activity, and structural conformation (visualized by cryo-EM). For instance, we 244 
already established that glycerol meets these two criteria, as it imposes hSARM1 compact 245 
conformation (Figure 2) and reduces NADase activity (Figure 3F). Curiously, glycerol was found 246 
to occupy the active site of the hSARM1 TIR domain in a crystal structure (PDB code 6O0R 247 
(Horsefield et al., 2019)), directly linking structural data with enzymatic inhibition. However, the 248 
glycerol concentrations in which these in vitro experiments were conducted were very high (15-249 
18% for the NADase activity assay and cryo-EM, and 25-30% in the X-ray crystal structure), i.e. 250 
2-4 M, which is considerably higher than the estimated sub 1 mM concentrations of intracellular 251 
physiological glycerol (Li and Lin, 1983). Next, we considered ATP as a fit candidate to inhibit 252 
hSARM1, because ATP is the main energetic compound, with cellular concentrations between 1-253 
10 mM, which is depleted prior to cell death and axonal degeneration. Indeed, we found that ATP 254 
inhibits the NADase activity of hSARM1 in a dose-dependent manner (Figure 4A). However, it did 255 
not affect hSARM1 conformation as observed by 2D classification (Figure 4B). Therefore, it is 256 
possible that ATP inhibits hSARM1 through the TIR domain’s active site.  257 
It was reported that NAD+ levels drop in response to axon injury (Coleman and Hoke, 2020). 258 
Also, the ablation of the cytosolic NAD+ synthesizing enzymes NMNAT1 and 2 decreases 259 
cytoplasmic NAD+, and induces SARM1 activation (Gilley et al., 2015; Sasaki et al., 2016). 260 
Therefore, we postulated that it is the high physiological concentration of NAD+ itself, that may 261 
inhibit hSARM1 through ‘substrate inhibition’ - a general mechanism regulating the activity of 262 
many enzymes (Reed et al., 2010). Cryo-EM images show that adding 5mM NAD+ to hSARM1 263 
has a dramatic effect: >80% of the particles show the two-ring, compact conformation – in 264 
contrast to the <20% found in the absence of NAD+ (Figure 4B,C). To measure NAD+ substrate 265 
inhibition of hSARM1, we used a fluorescent assay with a wide concentration range of the NAD+ 266 
analog, etheno-NAD (eNAD) (mixed 1:10 mol/mol with regular NAD+). eNAD fluoresces upon 267 
hydrolysis (ex. λ = 330 nm, em. λ = 405 nm). The results showed a bell-shape curve (Figure 4D) 268 
with the highest rate of hydrolysis at 100µM NAD+ and a steady decrease in rate thereafter (at 269 
the higher concentrations). In addition, we used a direct reverse-phase HPLC monitoring of 270 
NAD+ consumption by hSARM1 compared with commercially available porcine brain NADase. 271 
While the rate of hydrolysis of porcine NADase was maintained between 50µM and 2mM NAD+, 272 
hSARM1 was almost completely inhibited at 2mM NAD+ (Figure 4E). 273 
 274 
2.7 Å resolution structure of NAD+ induced hSARM1 compact octamer  275 
Following evidence for NAD+ substrate inhibition of hSARM1 by cryo-EM 2D classification 276 
(Figure 4B,C) and enzymatic (Figure 4D,E) assays, we pursued a 3D structure determination of 277 
hSARM1 complexed with NAD+ at inhibiting concentrations. hSARM1, supplemented by 5mM 278 
NAD+, was imaged, reconstructed and refined to 2.7 Å resolution (Figure 5A), resulting in an 279 
excellent map (Figure 5 and Figure 5 - Figure supplement 1). The structure was largely identical 280 
to the GraFix-ed structure, further substantiating the validity of the latter (Figure 5B). Few 281 
structural differences can be observed between the NAD+ supplemented density map and that of 282 
the GraFix-ed hSARM1. The first difference is a 5Å shift in the position of the distal part of the 283 
TIR domain, and the second is a rearrangement of the secondary structure at the region of the 284 
‘crescent horns’, where the tips of ARM1 and ARM2 touch (Figure 5C, Figure 5 - Figure 285 
supplements 1 and 2A,B). In the same region, designated hereafter ‘ARM allosteric site’, an 286 
extra-density in the NAD+ supplemented map reveals the binding site of one NAD+ molecule, 287 
providing clear atomic details (Figure 5C, right panel). To probe into the function of the ARM 288 
allosteric site, we introduced point mutations, targeting three structural elements surrounding the 289 
NAD+ density. These elements were: ARM1 𝛂2; ARM1 𝛂5-6 loop; and the ARM1-ARM2 loop 290 
(Figure 5C,D, Figure 5 - Figure supplement 2). As a control, we introduced two other mutations in 291 
sites that we do not consider to be involved in hSARM1 inhibition or activation. We hypothesized 292 
that NAD+ binding at the ARM allosteric site stabilizes the ARM conformation by interacting with 293 
both ARM1 and ARM2, thereby promoting the hSARM1 compact auto-inhibited structure. 294 
Therefore, mutations in the allosteric site, that interfere with NAD+ binding, would diminish auto-295 
inhibition and allow hSARM1 activity in cell culture. Indeed, we found that two separate mutations 296 
in the ARM1 𝛂5-6 loop (L152A, and R157E) and one in the opposite ARM1-ARM2 loop (R322E) 297 
had a dramatic effect on hSARM1 activity, promoting cell death levels comparable to those 298 
induced by the ‘delARM’ ‘constitutively active’ construct, which is missing the entire ARM domain 299 
(Figure 5D). Two mutations (D314A and Q320A), that are also located at the ARM1-ARM2 loop 300 
but their side chains positioned away from the NAD+ molecule, did not induce hSARM1 301 
activation. As expected, the control mutations E94R and K363A did not affect hSARM1 activity 302 
either. Surprisingly, mutating the bulky W103, which stacks with the NAD+ nicotinamide ring, into 303 
an alanine had only a small effect. Nevertheless, W103D mutation did have strong activating 304 
effect, leading to the notion that NAD+ contacts with the W103 side chain may be dispensable for 305 
the NAD+ inhibitory effect, but interference (as by the aspartate side chain) cannot be tolerated.  306 
Interestingly, we did not find a density indicating the presence of an NAD+ molecule at the TIR 307 
domain active site, although this site is not occluded by the ARM domain (Figure 5 - Figure 308 
supplement 1B). Possibly, the BB loop, which is interacting with a neighboring ARM domain 309 
(Figure 5 - Figure supplement 1B), assumes a conformation that prevents NAD+ entry into the 310 
binding cleft.  311 
Another conspicuous distinction between the two maps is the difference in local resolution of the 312 
domains. The difference between the highest and lowest resolution domains (SAM>ARM>TIR) is 313 
more obvious in the GraFix-ed structure than the NAD+ supplemented structure (Figure 2 - 314 
Figure supplement 2). This implies that there is more flexibility in the GraFix-ed structure.  A likely 315 
reason for the difference in map homogeneity is that, while the compact arrangement in the 316 
GraFix-ed structure is artificially imposed by high glycerol concentration, the NAD+ supplement 317 
seems to induce a more natural compact folding.  318 
 319 
Discussion 320 
Our octamer ring structure of a near-intact hSARM1 reveals an inhibited conformation, in which 321 
the catalytic TIR domains are kept apart from each other, unable to form close homodimers, 322 
which are required for their NADase activity. This inhibited conformation readily disassembles 323 
and gains most of its potential activity during protein purification, substantiating our hypothesis 324 
that a low-affinity cellular factor inhibits hSARM1 is lost in purification. We have tested a few 325 
candidate molecules and found that NAD+ induces a dramatic conformational shift in purified 326 
hSARM1, from a disassembled outer ring to a compact two-ring structure, through binding to a 327 
distal allosteric site from the TIR catalytic domain. Point mutations in this distal site promoted 328 
hSARM1 activity in cultured cells and demonstrates their key allosteric role for inhibition of the 329 
NADase activity. We also found that hSARM1 is inhibited in vitro by NAD+ for NADase activity, 330 
demonstrating a ‘substrate inhibition mechanism’, as was also reported by another recent study 331 
(Jiang et al., 2020). 332 
Following these results, we propose a model for hSARM1 inhibition in homeostasis and activation 333 
under stress (Figure 6). In this model, we suggest that hSARM1 is kept inhibited by NAD+ 334 
through its allosteric site, located at the ARM domain ‘horns’ junction that induces the compact 335 
inhibited conformation. This state persists as long as NAD+ remains at normal cellular levels 336 
[these are controversial, and range between 0.1mM (Cambronne et al., 2016) to 0.4-0.8mM 337 
(Hara et al., 2019; Houtkooper et al., 2010; Liu et al., 2018b)]. However, upon a drop in the 338 
cellular NAD+ concentration below a critical threshold, such as in response to stress, NAD+ 339 
dissociates from the allosteric inhibitory site. This triggers the disassembly of the compact 340 
conformation, and the dimerization of TIR domains, which enables TIR’s NADase activity and 341 
NAD+ hydrolysis. The consequence is a rapid decrease in NAD+ cellular levels, leading to 342 
energetic catastrophe and cell death.  343 
This model seems to be at odds with another suggested mechanism (Bratkowski et al., 2020; 344 
Zhao et al., 2019) in which, following axon injury, an increase in NMN concentration triggers 345 
SARM1 activation. Regardless of the question whether axon injury actually leads to lasting NMN 346 
levels elevation (Di Stefano et al., 2015) or not (Sasaki et al., 2016), we believe that the two 347 
models can be easily reconciled, at least in the limited scope of the in-vitro enzymatic 348 
mechanism. It is likely that NMN, a moiety of NAD+, will form interactions with most of the ARM1 349 
residues as NAD+. By that, NMN will compete with NAD+ and prevent the formation of ARM1-350 
ARM2 NAD+ bridge, the latter stabilizing the inactive conformation of SARM1. Such NAD+ 351 
displacement would result with SARM1 NADase activation. Clearly, this will require high NMN 352 
concentrations to effectively compete-off the ARM1-ARM2 bound NAD+. Indeed, we show (Figure 353 
3E) that only 1mM NMN (but not 0.2mM) induce a moderate increase in SARM1 NADase activity 354 
at 50 µM NAD+.  355 
This finding casts some doubt over the prospects for activation by NMN to be naturally occurring 356 
in vivo, as it consistently appears that NMN concentrations are not higher than 5 µM, and in any 357 
case 10-200 times lower than that of NAD+ (Di Stefano et al., 2015; Liu et al., 2018b; Sasaki et 358 
al., 2016). Therefore, while NMN could activate SARM1 in-vitro, in cultured cells engineered to 359 
over produce NMN, or by exogenous supplement of NMN or NMN analogs, it is less likely to 360 
occur in-vivo. Suggesting that the release of substrate inhibition due to the drop in NAD+ levels is 361 
the key event in SARM1 activation.  362 
 363 
364 
Materials and methods 365 
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 366 
cDNA generation and subcloning. 367 
Cloning of all the constructs was made by PCR amplification from the complete cDNA 368 
clone (Imagene) of hSARM1 (uniprot: Q6SZW1). For expression in mammalian cell culture, the 369 
near-intact hSARM1w.t. (26ERL…GPT724) and the mutants hSARM1E642Q, hSARM1RR216-7EE, 370 
hSARMFP255-6RR, hSARM1RR216-7EE/FP255-6RR and delARM (387SAL…GPT724) constructs were ligated 371 
into a modified pEGFP-N1 mammalian expression plasmid which is missing the C-terminus GFP 372 
fusion protein, and includes N-terminal 6*HIS-Tag followed by a TEV digestion sequence. 373 
Assembly PCR mutagenesis (based on https://openwetware.org/wiki/Assembly_pcr) was used to 374 
introduce all the point mutations.  375 
 376 
Protein expression and purification 377 
For protein purification, SARM1w.t. and SARM1E642Q were expressed in HEK293F suspension cell 378 
culture, grown in FreeStyleTM 293 medium (GIBCO), at 37°C and in 8% CO2. Transfection was 379 
carried out using preheated (70°C) 40 kDa polyethyleneimine (PEI-MAX) (Polysciences) at 1mg 380 
of plasmid DNA per 1 liter of culture once cell density has reached 1*106 cells/ml. Cells were 381 
harvested 4- (in the case of SARM1w.t.) and 5- (in the case of SARM1 E642Q) days after transfection 382 
by centrifugation (10 min, 1500 x g, 4°C), re-suspended with buffer A (50mM Phosphate buffer 383 
pH 8, 400mM NaCl ,5% glycerol, 1mM DTT, 0.5mM EDTA, protease inhibitor cocktail from 384 
Roche) and lysed using a microfluidizer followed by two cycles of centrifugation (12000 x g 20 385 
min). Supernatant was then filtered with 45µm filter and loaded onto a pre-equilibrated Ni-chelate 386 
column. The column was washed with buffer A supplemented with 25mM Imidazole until a stable 387 
baseline was achieved. Elution was then carried out in one step of 175mM Imidazole, after which 388 
protein-containing fractions were pooled and loaded onto pre-equilibrated Superdex 200 HiLoad 389 
16/60 (GE Healthcare) for size exclusion chromatography and elution was performed with 25mM 390 
Phosphate buffer pH 8.5, 120 mM NaCl, 2.5% glycerol, and 1mM DTT. In SDS-PAGE Coomassie 391 
staining, SARM1 appears as a doublet band (Figure 1B). This is probably a result of N-terminal 392 
His-tag truncation in some of the SARM1 protein molecules, due to our observation that only the 393 
upper band appears in anti-His WB. Protein-containing fractions were pooled and concentrated 394 
using a spin concentrator to 1.5 mg/ml. The concentrated proteins were either split into aliquots, 395 
flash-frozen in liquid N2 and stored at -80°C for later cryo-EM visualization and enzymatic assays, 396 
or immediately subjected to a ‘GraFix’ (Kastner et al., 2008) procedure as follows. 397 
Ultracentrifugation was carried out using a SW41Ti rotor at 35,000rpm for 16 h at 4 °C in a 10–398 
30% glycerol gradient (prepared with gradient master-ip® BioComp Instruments, Fredericton, 399 
Canada), with a parallel 0–0.2% glutaraldehyde gradient, and with buffer composition of 25mM 400 
Phosphate buffer pH 8.5, 120mM NaCl, and 1mM DTT. The protein solution volume that was 401 
applied to GraFix was 0.4ml. After ultracentrifugation, the 12ml gradient tube content was 402 
carefully fractionated into 0.75ml fractions, supplemented with 10mM aspartate pH 8 to quench 403 
crosslinking, using a regular pipette. Most of the cross-linked protein was found at the fractions 404 
around 18% glycerol with minor amount at the bottom of the tube (See Figure 1B). Analysis was 405 
made by SDS-PAGE and the dominant 2-3 fractions were pooled and diluted by 25mM 406 
Phosphate buffer pH 8.5, 120mM NaCl, and 1mM DTT, so to reach a final glycerol concentration 407 
of 2.5%. The diluted sample was then concentrated using a 100KDa cutoff Centricon® spin 408 
concentrator to reach 1mg/ml protein concentration.  409 
 410 
Cryo-EM grids preparation 411 
Cryo-EM grids were prepared by applying 3 μl protein samples to glow-discharged (PELCO 412 
easiGlow™ Ted Pella Inc., at 15 mA for 1 minute) holey carbon grids (Quantifoil R 1.2/1.3, Micro 413 
Tools GmbH, Germany). The grids were blotted for 4 seconds and vitrified by rapidly plunging 414 
into liquid ethane at −182 °C using Leica EM GP plunger (Leica Microsystems, Vienna, Austria). 415 
The frozen grids were stored in liquid nitrogen until the day of cryo-EM data collection. 416 
 417 
Cryo-EM data acquisition and processing 418 
In this paper we present data that were collected with three separate cryo-electron microscopes: 419 
  1) F30 Polara in Ben-Gurion University, Israel was used for all sample preparation 420 
optimization. It was also used to collect data sets without and with potential inhibitors (shown in 421 
Figure 1C and the ATP and NMN supplemented classes in Figure 4B). Finally, it was used for 422 
data collection and the 3D reconstructions presented in Figure 1D.  423 
Samples were imaged under low-dose conditions on a FEI Tecnai F30 Polara microscope (FEI, 424 
Eindhoven) operating at 300kV. Datasets were collected using SerialEM (Mastronarde, 2005) on 425 
a K2 Summit direct electron detector fitted behind an energy filter (Gatan Quantum GIF) with a 426 
calibrated pixel size of 1.1Å. The energy filter was set to remove electrons > ±10eV from the 427 
zero-loss peak energy. The defocus range was set from -1.0μm to -2.5μm. The K2 summit 428 
camera was operated in counting mode at a dose rate of 8 electrons/pixel/second on the camera. 429 
Each movie was dose fractionated into 50 image frames, with total electron dose of 80ē/Å2. 430 
Dose-fractionated image stacks were aligned using MotionCorr2 (Li et al., 2013), and their 431 
defocus values estimated by Gctf (Zhang, 2016). The sum of the aligned frames was used for 432 
further processing and the rest of the processing was done in Cryosparc V2 (Punjani et al., 433 
2017). Particles were auto-picked and subjected to local motion correction to correct for beam-434 
induced drift and then 2D classification with 50 classes. The best (based on shape, number of 435 
particles and resolution) classes were manually selected containing 5459 (for hSARM1E642Q) and 436 
43868 (for SAM1-2) particles. 1 initial 3D reference was prepared from all particles and 3D 437 
refinement imposing C8 symmetry resulted the final map.  438 
2) Titan Krios in ESRF CM01 beamline (Kandiah et al., 2019) at Grenoble, France, was 439 
used for data collection and 3D reconstruction of the GraFix-ed (Figures 2 and 3) and NAD+ 440 
supplemented (Figure 5, Figure 5 - Figure supplement 1) samples.  441 
Frozen grids were loaded into a 300kV Titan Krios (ThermoFisher) electron microscope (CM01 442 
beamline at ESRF) equipped with a K2 Summit direct electron-counting camera and a GIF 443 
Quantum energy filter (Gatan). Cryo-EM data were acquired with EPU software (FEI) at a 444 
nominal magnification of ×165,000, with a pixel size of 0.827 Å. The grid of the GraFix-ed sample 445 
was collected in two separate sessions. The movies were acquired for 7 s in counting mode at a 446 
flux of 7.06 electrons per Å2 s–1 (data collection 1: 3748 movies) or 6.83 electrons per Å2 s–1 (data 447 
collection 2: 4070 movies), giving a total exposure of ~50 electrons per Å2 and fractioned into 448 
40 frames. 7302 movies of the of the NAD+ supplemented grid sample were acquired for 4 s in 449 
counting mode at a flux of 7.415 electrons per Å2 s–1, giving a total exposure of ~40 electrons per 450 
Å2 and fractioned into 40 frames. For each data collection a defocus range from −0.8μm to 451 
−2.8 μm were used. Using the SCIPION wrapper (Martinez et al., 2020) the imported movies 452 
were drift-corrected using MotionCor2 and  CTF  parameters  were estimated  using Gctf for real-453 
time evaluation. Further data processing was conducted using the cryoSPARC suite. Movies 454 
were motion-corrected and contrast transfer functions were fitted. Templates for auto-picking 455 
were generated by 2D classification of auto picked particles. For the GraFix-ed data, template-456 
based auto-picking produced a total of 658,575 particles, from which 147,232 were selected 457 
based on iterative reference-free 2D classifications for reconstruction of the GraFix-ed structure. 458 
In the case of the NAD+ supplemented data, a total of 335,526 particles were initially picked, from 459 
which 159,340 were selected based on iterative reference-free 2D classifications for 460 
reconstruction. Initial maps of both GraFix-ed and NAD+ supplemented hSARM1 were calculated 461 
using Ab-initio reconstruction and high-resolution maps were obtained by imposing C8-symmetry 462 
in non-uniform 3D refinement. Working maps were locally filtered based on local resolution 463 
estimates. 464 
3) Talos Glacios in EMBL, Grenoble, France was used for data collection and the 465 
comparison of NAD+ supplemented and not-supplemented samples (Figure 4A,B).  466 
Frozen grids were loaded into a 200kV Talos Glacios (ThermoFisher) electron microscope 467 
equipped with a Falcon3 direct electron-counting camera (ThermoFisher). Cryo-EM data were 468 
acquired with EPU software (FEI) at a nominal magnification of ×120,000, with a pixel size of 469 
1.224Å. For the comparative analysis of NAD+ supplement, the grids of +5mM NAD and no NAD 470 
sample were screened and collected. The movies were acquired for 1.99 s in linear mode at a 471 
flux of 21.85 electrons per Å2 s–1 (data collection +5mM NAD: 2408 movies; no NAD: 2439 472 
movies) giving a total exposure of ~44 electrons per Å2 and fractioned into 40 frames. For each 473 
data collection a defocus range from −0.8μm to −2.8μm was used. Warp (Tegunov and Cramer, 474 
2019) was used for real-time evaluation, for global and local motion correction and estimation of 475 
the local defocus. The deep learning model within Warp detected particles sufficiently. Inverted 476 
and normalized particles were extracted with a boxsize of 320 pixels.  477 
466135 particles of the +5 mM NAD data, and 414633 particles of the ‘no NAD+’ set were 478 
imported into Cryosparc for further processing and subjected to a 2D circular masked 479 
classification with 100 classes. The class averages were manually evaluated and designated as 480 
either ‘full ring’ or ‘core ring’.  481 
 482 
Cell viability assay  483 
HEK293T cells were seeded onto lysine precoated 24 well plates (100,000 cells in 484 
each well) in final volume of 500 µL of DMEM (10% FBS) and incubated overnight at 37°C under 485 
5% CO2. They were then transfected with different hSARM1 constructs using the calcium 486 
phosphate-mediated transfection protocol (Kingston et al., 2003), with addition of 25µM 487 
Chloroquine (SIGMA) right before the transfection. 6 hours after transfection, the chloroquine-488 
containing DMEM was replaced by fresh complete medium. After 24 hours the medium was 489 
removed and replaced with 0.03 mg/ml Resazurin sodium salt (SIGMA) dissolved in Phenol Red 490 
free DMEM. All plates were then incubated for 1h at 37°C and measured using a SynergyHI 491 
(BioTek) plate reader at 560nm excitation and 590nm emission wavelengths. All fluorescent 492 
emission readings were averaged and normalized by subtracting the Resazurin background 493 
(measured in wells without cells) and then divided by the mean fluorescence emission from cells 494 
transfected by the empty vector (pCDNA3).   495 
HEK293F cells were seeded in 24 well plates (1 million cells in each well) in a final 496 
volume of 1 mL of FreeStyleTM 293 medium (GIBCO). The cells were transfected with 1 ug DNA 497 
as described before and incubated at 37°C and in 8% CO2. Live cells were counted using the 498 
trypan blue viability assay every 24 hours for three days. Three repeats were performed for each 499 
construct. 500 
Noteworthy, the identity of the HEK293F and HEK293T cell lines is clear by their 501 
different growth conditions and features. 502 
 503 
in vitro hSARM1 NADase activity assays 504 
For quantitation of hSARM1 NADase activity and the inhibitory effect of selected 505 
compounds (Figure 3F; Figure 4A and D), purified hSARM1w.t. and hSARM1E642Q proteins were 506 
first diluted to 400 nM concentration in 25 mM HEPES pH 7.5, 150mM NaCl, and then mixed in 507 
25°C with 1uM of NAD+ (in the same buffer) with a 1:1 v/v ratio. All inhibitors were diluted with 508 
the same buffer, and the pH values were measured and if necessary titrated to 7.5. Inhibitors 509 
were pre-incubated for 20 min with hSARM1 in 25°C before mixing with NAD+. At designated 510 
time points, reactions were quenched by placing the reaction tubes in 95°C for 2 min.  511 
Measurement of NAD+ concentrations was made by a modified enzymatic coupled cycling assay 512 
(Kanamori et al., 2018). The reaction mix, which includes 100 mM Phosphate buffer pH=8, 0.78% 513 
ethanol, 4uM FMN (Riboflavin 5’-monophosphate sodium salt hydrate), 27.2 U/ml Alcohol 514 
dehydrogenase (SIGMA), 1.8 U/ml Diaphorase (SIGMA) and freshly dissolved (in DDW) 8 uM 515 
Resasurin (SIGMA), was added to each sample at 1:1 (v/v) ratio and then transferred to a 384-516 
well black plate (Corning). Fluorescent data were measured using a SynergyHI (BioTek) plate 517 
reader at 554-nm excitation and 593-nm emission wavelengths. Standard curve equation for 518 
calculation of NAD+ concentration was created for each assay from constant NAD+ 519 
concentrations.  520 
eNAD-based NADase assay: eNAD (Nicotinamide 1,N6-ethenoadenine dinucleotide, 521 
SIGMA – N2630)  was solubilized in water and mixed with native NAD+ in ration of 1:10 (mol:mol) 522 
to a final stock concentration of 10mM. Serial dilutions were made with 25mM HEPES pH 7.5, 523 
150mM NaCl buffer and the final mix was transferred to a 384-well black plate (Corning). 524 
Reaction started by the addition of hSARM1 to a final concentration 400nM. Then, eNAD 525 
degradation rate was monitored by fluorescence reading (330-nm excitation and 405-nm 526 
emission wavelengths) of the plate using a SynergyHI (BioTek) in 25°C for 3 hours. For each 527 
NAD+ concentration, a control reaction without SARM1 was measured and subtracted from the 528 
+hSARM1 reading and the slope of the linear area was calculated. For the final plot, average of 529 
slopes from 3 separate assays for each concentration was calculated.      530 
HPLC analysis: Purified hSARM1w.t. was first diluted to 800nM in 25mM HEPES pH 531 
7.5, 150mM NaCl, and then mixed at 37°C with different concentrations of NAD+ (in the same 532 
buffer) in a 1:1 v/v ratio and incubated for 0, 5 and 30 min. 1:100 (v/v). BSA (NEB Inc. 20mg/ml) 533 
was included, and reactions were stopped by heating at 95°C for 2 minutes. Where specified, 534 
NMN (Sigma-Aldrich - N3501) was added in different concentrations. For control, NAD+ 535 
consumption was compared to a commercially available porcine brain NADase 0.025 units/ml 536 
(Sigma-Aldrich - N9879). HPLC measurements were performed using a Merck Hitachi Elite 537 
LaChrom HPLC system equipped with an autosampler, UV detector and quaternary pump. HPLC 538 
traces were monitored at 260nm and integrated using EZChrom Elite software. 10 μL of each 539 
sample were injected onto a Waters Spherisorb ODS1 C18 RP HPLC Column (5 μm particle size, 540 
4.6 mm × 150 mm ID). HPLC solvents are; A: 100% methanol; B: 120mM sodium phosphate pH 541 
6.0; C double-distilled water (DDW). The column was pre-equilibrated with B:C mixture ratio of 542 
80:20. Chromatography was performed at room temperature with a flow rate of 1.5 ml/min. Each 543 
analysis cycle was 12 min long as follows (A:B:C, v/v): fixed 0:80:20 0-4 min; gradient to 20:80:0 544 
4-6 min; fixed 20:80:0 from 6-9 min, gradient to 0:80:20 from 9-10 min; fixed 0:80:20 from 10-12 545 
min. The NAD+ hydrolysis product ADPR was eluted at the isocratic stage of the chromatography 546 
while NAD+ elutes in the methanol gradient stage. 547 
 548 
Calculation of SARM1 kinetic parameters 549 
For Vmax and Km determination, the NADase activity assay was performed with several different 550 
NAD+ substrate concentrations and sampled in constant time points. For each NAD+ 551 
concentration, linear increase zone was taken for slope (V0) calculation. All data were then fitted 552 
to the Michaelis-Menten equation using non-linear curve fit in GraphPad Prism software. Kcat was 553 
calculated by dividing the Vmax with protein molar concentration. 554 
 555 
Model building and refinement 556 
GraFix-ed map 557 
The monomers of known octameric X-ray structures of the hSARM1 SAM1-2 domains (PDBs 6qwv 558 
and 6o0s) were superimposed by the CCP4 (Winn et al., 2011) program GESAMT (Krissinel, 559 
2012) to identify the conserved regions. The model chosen for MR (molecular replacement) 560 
contained single polypeptide residues A406-A546 from the PDB 6qwv (SAM Model). 561 
Superposition of all available structures of the hSARM1 TIR domain (PDBs 6o0q, 6o0r, 6o0u, 562 
6o0qv, and 6o1b) indicated different conformations of the protein main chain for the BB loop 563 
region (a.a 593-607). Two different MR models were prepared for the hSARM1 TIR domain. TIR 564 
Model 1 contained regions 562-592 and 608-700 of the high-resolution structure (PDB 6o1b). TIR 565 
Model 2 represented assembly of superimposed polyalanine models of all the available hSARM1 566 
TIR domains. Models were positioned into the density map by MR with use of phase information 567 
as implemented in program MOLREP (Vagin and Teplyakov, 2010). The shell scripts of the 568 
MOLREP EM tutorial were downloaded from https://www.ccpem.ac.uk/docs.php and adapted to 569 
allow simultaneous positioning of eight molecular symmetry related SARM1 copies (MOLREP 570 
keyword NCS 800). 571 
The search protocol involved Spherically Averaged Phased Translation Function (SAPTF; 572 
MOLREP keyword PRF Y). The recent version of MOLREP (11.7.02; 29.05.2019) uses 573 
modification of the original SAPTF protocol (Vagin and Isupov, 2001), adapted for work with EM 574 
density maps (Alexey Vagin, private communication). It now performs the Phased RF (rotation 575 
function) search step in a bounding box of the search model and not in the whole (pseudo) unit 576 
cell. Instead of Phased Translation Function step, MOLREP performs Phased RF search at 577 
several points in the vicinity of SAPTF peak and, in addition, applies Packing Function to potential 578 
solutions. 579 
The SAM Model was positioned into the GraFix-ed density map with a score (Map CC times 580 
Packing Function) of 0.753. The positioned SAM Model was used as a fixed model in MOLREP 581 
when searching for the TIR domain. The TIR Model 1 was positioned with a score of 0.582. The 582 
MR search with the TIR Model 2 gave essentially the same solution with a lower overall score of 583 
0.559, but higher contrast. With both SAM1-2 and TIR domains positions fixed, the MR search for 584 
an ideal 10-residue -helical model allowed location of 64 fragments (8 helices per SARM1 585 
monomer) with scores in the range of 0.78-0.81. These helical fragments were used for building 586 
of the ARM domain in Coot (Emsley et al., 2010). The quality of the high resolution GraFix-ed 587 
density map was sufficient for assignment of side chains for all ARM domain residues. The TIR 588 
domain BB loop region (a.a 595-607) was built to fit a relatively poor density map in a 589 
conformation different to those observed in X-ray structures. The model was refined using 590 
REFMAC5 (Murshudov et al., 2011). Side chains of some Lys residues had blobs of undescribed 591 
density attached to them. These were modelled as glutaraldehyde ligands. Geometrical restraints 592 
for the di-glutaraldehyde molecule and its links to side chains of Lys residues were prepared 593 
using JLIGAND (Lebedev et al., 2012). The dictionary file was manually edited to allow links to 594 
more than a single lysine residue.  595 
 596 
NAD-supplemented map 597 
Originally, the refined full-length GraFix-ed model was positioned by MR into the NAD-598 
supplemented density map, but differences in the relative positions of the hSARM1 domains were 599 
apparent. Therefore, MR search was conducted for separate hSARM1 domains. The SAM Model 600 
was positioned with a score of 0.653 into this map. With the fixed SAM Model the TIR Model 1 601 
was found with score of 0.594. With fixed SAM and TIR Models, the ARM domain from the 602 
GraFix model was found with score of 0.623. The BB-loop of the TIR domain was built into well-603 
defined density map in a conformation not observed in any of the X-ray structures and different to 604 
that in the GraFix-ed model. A low sigma cutoff map allowed modelling of the loop connecting the 605 
SAM and TIR domains. Inspection of the maps indicated NAD+ binding accompanied by 606 
structural re-arrangement of the ARM1-ARM2 linker region (a.a. 312-324).  607 
 608 
Accession numbers 609 
Coordinates and structure factors have been deposited in the Protein Data Bank with 610 
accession numbers 6ZFX, 7ANW, 6ZG0, 6ZG1, and in the EMDB with accession numbers 611 
11187, 11834, 11190, 11191 for the GraFix-ed, NAD+ supplemented, not treated, and SAM1-2 612 




Figure 1. Domain organization and cryo-EM analysis of purified hSARM1. 617 
A) Color-coded organization and nomenclature of the SARM1 ARM, SAM, and TIR domains. The 618 
position of mitochondrial localization signal is presented at the N terminus of the protein. Two 619 
constructs are used in this study, both missing the mitochondrial N-terminal sequence. 620 
hSARM1E642Q is a NADase attenuated mutant that was used in all the structural and some of the 621 
biochemical experiments; while hSARM1w.t. was used in the NADase and cellular experiments. B) 622 
hSARM1 protein preparations. Presented are SDS-PAGE analyses of size-exclusion 623 
chromatography fractions after the initial metal-chelate chromatography step. Note the higher 624 
yield of hSARM1E642Q compared to hSARM1w.t., and the doublet SARM1 bands, the result of a 625 
partial N-terminal his-tag digestion. The white arrow indicates the fraction used for the 626 
subsequent GraFix step shown at the right panel, where the approximate glycerol concentrations 627 
of each fraction are indicated. C) Most-prevalent 2D class averages of hSARM1E642Q protein 628 
preparations. A dramatic difference can be seen between the previously-conducted negative 629 
stain analysis (top panel, as in (Sporny et al., 2019)) and typical cryo-EM (middle panel). While 630 
the negative stain average clearly shows inner and peripheral rings (see illustration in the bottom 631 
panel), most cryo-EM classes depict only the inner ring, and some a partial outer ring assembly. 632 
Note that a gradient fixation (GraFix) protocol was applied before the negative stain but not the 633 
cryo-EM measurements. D) 3D cryo-EM reconstructions of hSARM1E642Q (top panel) and SAM1-2 634 
(bottom panel) and docking of the SAM1-2 crystal structure (PDB code 6QWV) into the density 635 
maps, further demonstrating that only the inner, SAM1-2 ring is well-ordered in cryo-EM of purified 636 
hSARM1E642Q.  637 
 638 
  639 
 640 
 641 
Figure 1 - Figure supplement 1. Structure-based sequence alignment of the SARM1 of human, 642 
mouse, zebrafish and the C. elegans homolog TIR-1. Color coded highlights and Uniprot protein 643 
accession numbers are listed below. 644 










electron microscope Titan Krios Titan Krios F30 Polara F30 Polara 
Cryo-EM acquisition and processing 
EMDB accession # 11187 11834 11190 11191 
Magnification 165,000x 165,000x 200,000 200,000 
Voltage (kV) 300 300 300 300 




) 50 40 80 80 
Defocus range (µM) -0.8 to -2.8 -0.8 to -2.8 -1.0 to -2.5 -1.0 to -2.5 
Pixel size (Å) 0.827 0.827 1.1 1.1 
Symmetry imposed C8 C8 C8 C8 
Initial particles 658,575  335,526 26,496 416,980 
Final particles 147,232  159,340 5,410 43,868 
Resolution (masked FSC = 
0.143, Å) 
2.88 2.7 7.7 3.77 
Model Refinement 
PDB ID 6ZFX 7ANW 6ZG0 6ZG1 
Model resolution (FSC = 
0.50/0.143Å) 
3.6 / 2.9 2.9 / 2.7   
Model refinement resolution 2.88 2.70   
Non-hydrogen atoms 39,856 40,560     
Residues 5,080 5,176     
RMS deviations 
Bond length (Å) 0.008 0.009   
Bond angle (°) 1.84 1.84   
Ramachandran plot 
Favored (%) 89.05 91.68   
Allowed (%) 10.95 8.32   
Disallowed (%) 0 0   
Rotamer Outliers (%) 5.73 6.64   
Validation 
MolProbity score 2.68 2.49   
Clashscore 10.08 6.66   
 645 
Table 1: Cryo-EM data acquisition, reconstruction and model refinement statistics. 646 
 647 
  648 
 649 
Figure 2. Cryo-EM structure of GraFix-ed hSARM1E642Q.  650 
A) Selected representation of 2D class averages used for the 3D reconstruction. The number of 651 
particles that were included in each average are indicated at the top of each class. B-D) Cryo-EM 652 
density map color-coded as in (Figure 1A) and by chain. ‘Top view’ refers to the aspect of the 653 
molecule showing the TIR (red) and SAM2 (cyan) domains closest to the viewer, while in the 654 
‘bottom view’ the SAM1 (blue) domains and the illustrated mitochondrial N-terminal localization 655 
tag (green dot - was not included in the expression construct) are the closest. D) Side view 656 
representation of the structure, sliced at the frontal plane of the aspect presented in (B) and (C).  657 
 658 
  659 
 660 
Figure 2 - Figure supplement 1. A) Cartoon model of hSARM1. Color code is as in Fig. 1A. B) 661 
Architecture of the crescent-shaped ARM domain. The structure reveals that there are two ARM 662 
subdomains, one spanning res. 60-303 with five 3-helix (depicted as green, yellow and blue 663 
cylinders) ARM repeats, and the second (res. 322-400) with two repeats, all colored in orange. 664 
The SAM and TIR domains are represented as transparent blue and red surface, respectively.     665 
 666 
Figure 2 - Figure supplement 2. Resolution, angular distribution, and B-factor estimations of the 667 
Cryo-EM maps of GraFix-ed (upper panel) and NAD+ supplemented (bottom panel) hSARM1.  668 
Note that while the GraFix-ed map has an overall lower resolution, it has a heterogenous 669 
distribution with distinctive differences between the SAM, ARM and TIR regions. On the contrary, 670 
in the NAD+ supplemented map, resolution values are much more homogenous. 671 
 672 
Figure 3. Structural basis for hSARM1 auto-inhibition. 673 
A) Close-up of a tilted side view of the GraFix-ed hSARM1E642Q map (colored as in Figure 2A). 674 
Two neighboring ARM domains (yellow) are outlined by a black line and the NAD+ binding cleft of 675 
a TIR domain that is bound to the two ARMs is highlighted in green. The interfaces formed 676 
between the TIR and ARMs are designated as the ‘primary TIR docking site’ and the ‘secondary 677 
TIR docking site’. B) Two ‘open-book’ representations (in the same orientation) of the ‘primary 678 
TIR docking site’. Left – the TIR and ARM domains are colored as in (A), and the interface 679 
surfaces in gray are encircled by green dashed line. Site-directed mutagenesis sites are 680 
indicated. Right - amino acid conservation at the ‘primary TIR docking site’. Cyan through maroon 681 
are used to indicate amino acids, from variable to conserved, demonstrating an overall high level 682 
of conservation in this interface. C) Toxicity of the hSARM1 construct and mutants in HEK293T 683 
cells. The cells were transfected with hSARM1 expression vectors, as indicated. Cell viability was 684 
measured and quantified 24 h post-transfection using the fluorescent resazurin assay. While cell 685 
viability is virtually unaffected after 24 hr by ectopic expression of hSARM1w.t. and hSARM1E642Q, 686 
deletion of the inhibiting ARM domain (which results in the SAM1–2–TIR construct) induces 687 
massive cell death. Mutations at the ‘primary TIR docking site’ of the ARM domain also induce 688 
cell death, similar to the ‘delARM’ construct (three biological repeats, Student t test; ∗∗∗ p < 0.001; 689 
∗ p < 0.05; n.s: no significance). D) Kinetic measurement of purified hSARM1 NADase activity. 690 
Km and Vmax were determined by fitting the data to the Michaelis-Menten equation and are 691 
presented as mean ± SEM for three independent measurements.  692 
E) HPLC analysis of time dependent NAD+ consumption (50µM) by hSARM1, and further 693 
activation by NMN (0.2 and 1 mM).  Time points 0 (black), 5 (green), and 30 (red) minutes. Right 694 
graph shows the rate of ADPR product generation: no NMN (green), 0.2mM NMN (orange), 1mM 695 
NMN (red). While 0.2mM NMN has no visible effect, 1mM NMN increases hSARM1 activity by 696 
~30%. 697 
F) Glycerol inhibition of hSARM1 NADase in vitro activity was measured 20 minutes after adding 698 
0.5µM NAD+ to the reaction mixture. In the same way, hSARM1E642Q activity was measured and 699 
compared to that of hSARM1w.t., showing attenuated NADase activity of the former.  700 
  701 
 702 
Figure 4. NAD+ induces structural and enzymatic inhibition of hSARM1 703 
A) Inhibition of hSARM1 NADase activity by ATP was demonstrated and analyzed as in Figure 704 
3F. B) The structural effects of NAD+ and ATP were observed by cryo-EM based on appearance 705 
in 2D classification. Presented are the 10 most populated classes (those with the largest number 706 
of particles – numbers in green, 1st class is on the left) out of 50-100 from each data collection 707 
after the first round of particle picking and classification. By this analysis, the percentage of 708 
particles that present full, two-ring structure is 13% (no NAD+); 74% (5mM NAD+); and 4% 709 
(10mM ATP). C) Total number of particles with full ring assembly vs. those where only the inner 710 
ring is visible. Conditions of sample preparation, freezing, collection, and processing were 711 
identical, except for the NAD+ supplement in one of the samples. D) Rate of change in nucleotide 712 
fluorescence under steady-state conditions of eNAD hydrolysis by hSARM1. Reactions were 713 
initiated by mixing 400nM enzyme with different concentrations of 1:10 eNAD+:NAD+ (mol/mol) 714 
mixtures. Three repeats, standard deviation error bars. E) HPLC analysis of time dependent 715 
NAD+ consumption by hSARM1 and porcine brain NADase control in 50µM and 2mM. Time 716 
points 0 (black), 5 (green), and 30 (red) minutes. Inset graph shows the rate of ADPR product 717 
generation. While the rate of NAD+ hydrolysis by porcine NADase is maintained through 50µM 718 
and 2mM NAD+, hSARM1 is tightly inhibited by 2mM NAD+. 719 
  720 
 721 
Figure 5. 3D structure reveals an inhibitory ARM allosteric NAD+ binding site.  722 
A) Selected representation of 2D class averages used for the 3D reconstruction of 723 
hSARM1E642Q supplemented with 5mM of NAD+. The number of particles that were 724 
included in each class average are indicated. B) Color coded (as in Figure 1A) protein 725 
model docked in a transparent 2.7 Å cryo-EM density map (gray). C) When compared to 726 
the GraFix-ed map, without NAD+ supplement (left), an extra density appears at the 727 
‘ARM horns’ region in the NAD+ supplemented map (middle, right). The extra density is 728 
rendered in green and an NAD+ molecule is fitted to it. The NAD+ is surrounded by three 729 
structural elements, as indicated on the right panel. The NAD+ directly interacts with the 730 
surrounding residues: the nicotinamide moiety is stacked onto the W103 sidechain rings; 731 
the following ribose with L152 and H190; R110 form salt bridge with phosphate alpha 732 
(proximal to the nicotinamide), while the beta phosphate (distal to the nicotinamide) form 733 
salt bridges with R110 and R157. The map density at the distal ribose and adenosine 734 
moieties is less sharp, but clearly involves interactions with the ARM2 R322, G323 and 735 
D326. In this way, activation by NMN, that lacks the distal phosphate, ribose and 736 
adenosine, can be explained by binding to ARM1 while preventing the bridging 737 
interactions with ARM2. D) Toxicity of the hSARM1 construct and mutants in HEK293F 738 
cells. The cells were transfected with hSARM1 expression vectors, as indicated. Viable 739 
cells were counted 48 (bars in gray) and 72 (bars in black stripes) hours post-740 
transfection. Moderate reduction in cell viability due to ectopic expression of hSARM1w.t. 741 
becomes apparent 72 hours after transfection, when compared with the NADase 742 
attenuated hSARM1E642Q, while the ‘delARM’ construct marks a constitutive activity that 743 
brings about almost complete cell death after three days. Mutations at the ARM1 𝛂5-6 744 
and ARM1-ARM2 loops induce cell death at a similar level as the ‘delARM’ construct, 745 
while the control mutations and W103A did not show increased activity (three biological 746 
repeats, Student t test; ∗∗∗ p < 0.001; ∗ p < 0.05; n.s: no significance). 747 
  748 
 749 
 750 
Figure 5 - Figure supplement 1. Cartoon model and density map (in transparent gray) of the 751 
NAD+ supplemented hSARM1. Color code is as in Fig. A1. A) A zoom-in bottom view with 752 
indication of the ‘ARM horns’ region. NAD+ densities are in green. Note the ARM domain 753 
interactions with neighboring SAM and ARM domains. B) A zoom-in view of the TIR domain 754 
docking onto two neighboring ARM domains. The NAD+ binding cleft and BB loop are indicated. 755 
C) Density map (in mesh) showing a close-up view of isolated segments of the ARM, SAM and 756 
TIR sections. The backbone and side chains are represented as sticks and colored in yellow, 757 
blue, and red, respectively, as in Fig. 1A. 758 
  759 
 760 
Figure 5 - Figure supplement 2. Zooming-in on the ARM allosteric NAD+ binding site.  761 
A, B) The principle structural rearrangements in the ARM domain are presented as simplify 762 
illustration based on a comparison between the GraFix-ed (A) and the NAD+ supplemented (B) 763 
SARM1 cryo-EM maps. The ARM1 and ARM2 subdomains are depicted in yellow and orange, 764 
respectively, and the ARM1 𝛂2-3 loop and ARM1 and ARM2 are highlighted. C) 2D Ligplot 765 
(Wallace et al., 1995) diagram details the hydrogen bonds, salt bridges and hydrophobic 766 
interactions between NAD+ and SARM1, where ARM1 residues are colored in yellow, and ARM2 767 
residues - in orange. The NMN moiety of NAD+ is outlined by a gray line drawing. According to 768 
this analysis, the NMN moiety mostly interacts (but not only) with ARM1 residues: W103, L104, 769 
E149, Q150, L152, V153, H190, and has a partial interaction with R110. S316 and D317 of ARM2 770 
also interact with the NMN moiety. The adenosine half of NAD+ mostly interacts (but not only) 771 
with ARM2 residues: Q320, G321, R322, G323, and D326. R110 and R157 of ARM1 also interact 772 
with the adenosine half.  773 
 774 
  775 
 776 
Figure 6. A model for hSARM1 inhibition and activation.   777 
In homeostasis, the cellular NAD+ concentration is high enough and binds to an allosteric site 778 
that drives hSARM1 compact conformation. In this conformation, the catalytic TIR domains (red) 779 
are docked on ARM domains (yellow) apart from each other, unable to form close dimers 780 
required for NAD+ catalysis. When cellular NAD+ levels drop as a result of reduced NAD+ 781 
synthesis (e.g. inhibition of NMNAT1/2) or increased NAD+ consumption, the inhibiting NAD+ 782 
molecules fall off hSARM1, leading to the disintegration of the ARM-TIR outer ring assembly. Still 783 
held by the constitutively-assembled SAM inner ring, the now-released TIR domains are at a high 784 
local concentration that facilitates their dimerization and ensued NADase activity. When released 785 
from allosteric inhibition, hSARM1 is only subjected to competitive inhibition such as by its 786 
products ADPR and NAM, which are not found in high enough concentrations to block its activity 787 
entirely. This leads to an almost complete consumption of the NAD+ cellular pool and to an 788 
energetic catastrophe from which there may be no return.  789 
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